Trial Profile
A Prospective, Multicenter, Open-Label Study to Assess Population Pharmacokinetics and Safety of Intravenous Ceftolozane/Tazobactam in Adult Cystic Fibrosis Patients Admitted With Acute Pulmonary Exacerbation
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 14 Dec 2023
Price :
$35
*
At a glance
- Drugs Ceftolozane/tazobactam (Primary)
- Indications Cystic fibrosis; Pseudomonal infections
- Focus Pharmacokinetics
- 22 Aug 2016 Status changed from recruiting to completed, as per an article published in the Antimicrobial Agents and Chemotherapy
- 22 Aug 2016 Results published in the Antimicrobial Agents and Chemotherapy
- 12 Nov 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.